Circadian variation in intestinal dihydropyrimidine dehydrogenase (DPD) expression: A potential mechanism for benefits of 5FU chrono-chemotherapy

Surgery

Volumn 146, Issue 2, 2009, Pages 269-273

  Abolmaali, Kamran ^a,b   Balakrishnan, Anita ^a,b,d   Stearns, Adam T ^a,b,e   Rounds, Jan ^a   Rhoads, David B ^a,c   Ashley, Stanley W ^a,b   Tavakkolizadeh, Ali ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CHRONOTHERAPY; CIRCADIAN RHYTHM; COLON MUCOSA; GASTROINTESTINAL DISEASE; JEJUNUM MUCOSA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLEEP WAKING CYCLE; STATISTICAL ANALYSIS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CIRCADIAN RHYTHM; COLON; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG CHRONOTHERAPY; FLUOROURACIL; INTESTINAL MUCOSA; JEJUNUM; MALE; RATS; RATS, SPRAGUE-DAWLEY; THYMIDYLATE SYNTHASE;

EID: 67650526404     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2009.05.005     Document Type: Article

References (25)

1. Parker W.B., and Cheng Y.C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48 (1990) 381-395
2. Longley D.B., Harkin D.P., and Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3 (2003) 330-338
3. Ezzeldin H., and Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 4 (2004) 181-189
4. Lokich J. 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 88 (2000) 2425-2426
5. Fata F., Ron I.G., Kemeny N., O'Reilly E., Klimstra D., and Kelsen D.P. 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 86 (1999) 1129-1134
6. Levi F., Zidani R., and Misset J.L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350 (1997) 681-686
7. Levi F.A., Zidani R., Vannetzel J.M., Perpoint B., Focan C., Faggiuolo R., et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 86 (1994) 1608-1617
8. Bjarnason G.A., Kerr I.G., Doyle N., Macdonald M., and Sone M. Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients. Cancer Chemother Pharmacol 33 (1993) 221-228
9. Porsin B., Formento J.L., Filipski E., Etienne M.C., Francoual M., Renee N., et al. Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression. Eur J Cancer 39 (2003) 822-828
10. Raida M., Kliche K.O., Schwabe W., Hausler P., Clement J.H., Behnke D., et al. Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls. J Cancer Res Clin Oncol 128 (2002) 96-102
11. Grem J.L., Yee L.K., Venzon D.J., Takimoto C.H., and Allegra C.J. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother Pharmacol 40 (1997) 117-125
12. Stearns A.T., Balakrishnan A., Rounds J., Rhoads D.B., Ashley S.W., and Tavakkolizadeh A. Capsaicin-sensitive vagal afferents modulate posttranscriptional regulation of the rat Na+/glucose cotransporter SGLT1. Am J Physiol Gastrointest Liver Physiol 294 (2008) G1078-G1083
13. Halberg F., Haus E., Cardoso S.S., Scheving L.E., Kuhl J.F., Shiotsuka R., et al. Toward a chronotherapy of neoplasia: tolerance of treatment depends upon host rhythms. Experientia 29 (1973) 909-934
14. Boughattas N.A., Levi F., Fournier C., Lemaigre G., Roulon A., Hecquet B., et al. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. Cancer Res 49 (1989) 3362-3368
15. Giacchetti S., Bjarnason G., Garufi C., Genet D., Iacobelli S., Tampellini M., et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24 (2006) 3562-3569
16. Levi F., and Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 47 (2007) 593-628
17. Harris B.E., Song R., Soong S.J., and Diasio R.B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50 (1990) 197-201
18. Krugluger W., Brandstaetter A., Kallay E., Schueller J., Krexner E., Kriwanek S., et al. Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors. Cancer Res 67 (2007) 7917-7922
19. Heggie G.D., Sommadossi J.P., Cross D.S., Huster W.J., and Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47 (1987) 2203-2206
20. Amatori F., Di Paolo A., Del Tacca M., Fontanini G., Vannozzi F., Boldrini L., et al. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. Pharmacogenet Genomics 16 (2006) 809-816
21. Tanaka-Nozaki M., Onda M., Tanaka N., and Kato S. Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels. Clin Cancer Res 7 (2001) 2783-2787
22. Tsuchida M., Yamato Y., Hashimoto T., Shinohara H., Umezu H., Yoshiya K., et al. Expression of 5-fluorouracil-related enzymes in lung cancer: ELISA characterizes enzyme activity and messenger RNA expression. Oncol Rep 21 (2009) 1037-1043
23. Lincoln II D.W., Hrushesky W.J., and Wood P.A. Circadian organization of thymidylate synthase activity in normal tissues: a possible basis for 5-fluorouracil chronotherapeutic advantage. Int J Cancer 88 (2000) 479-485
24. Okumura K., Shiomi H., Mekata E., Kaizuka M., Endo Y., Kurumi Y., et al. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. Oncol Rep 15 (2006) 875-882
25. Ichikawa W., Uetake H., Shirota Y., Yamada H., Nishi N., Nihei Z., et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9 (2003) 786-791